Alberto García-Basteiro, galardonado con el XX Premio Fundación Banco Sabadell a la Investigación Biomédica
Islobal researcher Alberto García-Bastiro has received the XX Banco Sabadell Foundation Award for biomedical research, an award that recognizes his work in the Development of new tools for diagnosis, treating and preventing tuberculosis, specialization in vulnerable populations. The IX Award for Science and Engineering, by Ootro -LADLA, has been given to ICREA research at the Institute of Computational Chemistry and Catalysis (IQCC) Sílvia Osuna, for its study in Computer Design of Enzymes of Medical Interest and Pharmacéy.
Alberto García-Bastiro is an associated research professor at the Institute of Global Health of Barcelona (ISGlobal), an attached doctor of the Preventive Medicine Service Epidemiology of the Clinic Hospital of Barcelona and Centralases of the Investin in the research in tuberulosis in the Center of Investi-Investen. In Health of Manhiça (CISM), in Mozambique. Has made innovative contributions in research on the tuberculosisSpecial in the areas of Clinical Epidemiology and New Diagnostic Methods.
In addition to contributing to Characterize the disease In Africa it subshaies now Identify risk factorsHas also carried out a end Pioneer studies on new diagnoses. These include the evaluation of molecular tests in unconventional samples (urine, feces, among others) for the deca Mycobacterium tuberculosis In vulnerable populations, main children and patients with HIV. He has also conducted epidemiological studies that have generated new knowledge about the natural history of tuberculosis. In this way, the jury has highlighted his Contribution to the competition of the different stages of tuberculosis And to the impulse of Innovative strategieslike the Messenger RNA -based vaccines (MNA).
Realmento, Alberto García-Bastiro coordinates both multicenter studies and clinical trials. «This award is a recognition of the Upoquio, based on Mozambique and Spain, which works to reduce the impact of this infectious fervency,» said García-Bastiro. «Our last objective is to reduce its incidence and mortality.»
